Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Read More →
Resiliva 80 mg & 100 mg (Resmetirom): Uses, Treatment and Safety
Understanding Resiliva
Resiliva is identified on this website as a product containing resmetirom, a prescription medicine developed for the treatment of certain adults with metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis.
The stated Resiliva strengths are 80 mg and 100 mg. These figures describe the stated amount of active ingredient per dosage unit; they should not be confused with a patient’s prescribed daily dose.
Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist. It acts primarily in the liver, where it influences metabolic pathways involved in lipid regulation and liver fat accumulation.
The established U.S. reference product containing resmetirom is REZDIFFRA, developed and commercialized by Madrigal Pharmaceuticals. The U.S. Food and Drug Administration approved REZDIFFRA in March 2024 for a defined group of adults with noncirrhotic NASH and moderate to advanced fibrosis, in conjunction with diet and exercise. The European Union subsequently granted conditional marketing authorization for REZDIFFRA for a corresponding MASH population.
These regulatory decisions apply to the reference product and its approved labeling. They do not, by themselves, establish the regulatory status or interchangeability of Resiliva in any particular country.
What Is Resmetirom?
Resmetirom is an oral medicine belonging to the selective thyroid hormone receptor-beta agonist class. It was developed to target metabolic processes in the liver that contribute to the accumulation of fat and the progression of metabolic liver disease.
The liver performs essential functions, including processing nutrients, regulating fats, producing proteins and helping remove substances from the bloodstream. In people with MASH, excess fat in the liver is associated with inflammation and liver-cell injury. Over time, this process may lead to fibrosis, which is the formation of scar tissue.
Resmetirom activates THR-β, a receptor involved in hepatic metabolic regulation. Its effects can influence lipid metabolism and reduce liver fat. In clinical studies supporting the reference product’s approval, resmetirom also improved measures of MASH and liver fibrosis in a proportion of treated patients.
It is not a general treatment for every type of fatty liver disease, and it should not be described as a cure for liver fibrosis. Its use depends on the specific diagnosis, fibrosis stage, applicable prescribing information and the patient’s overall health.
What Is Resiliva Used For?
The therapeutic information associated with resmetirom concerns adults with noncirrhotic MASH/NASH and moderate to advanced liver fibrosis, generally corresponding to fibrosis stages F2 and F3 under the U.S. reference-product indication.
MASH is a form of metabolic liver disease in which excess fat is accompanied by inflammation and damage to liver cells. Fibrosis may develop when ongoing injury causes scar tissue to accumulate.
Resmetirom is used alongside dietary and lifestyle measures. It does not replace a clinician-directed plan for managing metabolic risk factors, diabetes, cholesterol abnormalities, obesity or other relevant health conditions.
The FDA-approved indication for REZDIFFRA is based on improvement in MASH and fibrosis, with continued approval potentially dependent on confirmation of clinical benefit in further studies. The medicine’s established indication should not be expanded to include cirrhosis, uncomplicated fatty liver or other liver diseases without appropriate evidence and regulatory authorization.
Important: The established reference-product indication does not automatically confirm that Resiliva itself is authorized for the same use. The product’s own registration and approved information should be checked with the relevant medicines regulatory authority.
Resiliva 80 mg and 100 mg: Strength Information
The strengths identified for Resiliva on this website are 80 mg and 100 mg. These strengths also exist for the U.S. reference product REZDIFFRA, which is supplied as oral tablets in 60 mg, 80 mg and 100 mg strengths.
| Product detail | Information |
|---|---|
| Website product name | Resiliva |
| Active ingredient stated | Resmetirom |
| Stated strengths | 80 mg and 100 mg |
| Medicine class | Selective THR-β agonist |
| Therapeutic area | MASH with liver fibrosis |
| Reference product | REZDIFFRA |
| Reference-product developer and commercial company | Madrigal Pharmaceuticals |
| Resiliva dosage form | Confirm using product-specific documentation |
| Resiliva manufacturer and authorization | Confirm using official product and regulatory records |
The existence of matching strengths does not prove that two products have identical formulations, manufacturing processes, excipients or regulatory status.
How Does Resmetirom Work?
Resmetirom selectively activates thyroid hormone receptor-beta in the liver. This receptor plays a role in the regulation of metabolic processes, including lipid handling.
By influencing these pathways, resmetirom is designed to reduce liver fat and improve disease-related changes in selected patients with MASH.
Its effects are different from those of medicines primarily intended to suppress the immune system or destroy cancer cells. Resmetirom targets metabolic pathways relevant to liver disease.
However, the medicine can still cause adverse reactions and interact with other medicines. Treatment should therefore be supervised by a qualified healthcare professional, with monitoring based on the official prescribing information and the patient’s clinical needs.
General Dosage and Administration
The appropriate dose depends on the applicable product labeling and individual patient factors.
Under current U.S. REZDIFFRA labeling, the recommended once-daily dose is based on actual body weight:
Adults weighing less than 100 kg: 80 mg once daily.
Adults weighing 100 kg or more: 100 mg once daily.
These are reference-product dosing instructions, not an individualized prescription for Resiliva. Before applying them to Resiliva, the product’s own prescribing information and authorization should be verified.
Patients should not select a dose based only on the strength printed on a package. They should not switch between strengths, take additional tablets or change the prescribed schedule without professional guidance.
The current reference-product labeling also provides specific administration instructions and guidance for interactions with other medicines. Patients should follow the instructions applicable to their prescribed product.
Important Safety Information
Resmetirom treatment requires attention to possible adverse reactions, liver health and drug interactions.
Important safety considerations in the REZDIFFRA prescribing information include:
Liver injury: The product labeling includes a warning concerning hepatotoxicity.
Gallbladder-related problems: Gallstones and inflammation of the gallbladder are among the reported concerns.
Medicine interactions: Resmetirom can interact with certain statins and medicines that affect the CYP2C8 enzyme.
Digestive symptoms: Diarrhea, nausea and other gastrointestinal effects can occur.
Other adverse reactions: Itching, vomiting, constipation, abdominal discomfort and dizziness are among the reported adverse reactions.
Seek medical advice promptly if symptoms suggest a significant adverse reaction. Yellowing of the skin or eyes, dark urine, severe abdominal pain or unusual persistent fatigue warrant medical assessment. Severe or rapidly worsening symptoms require urgent care.
Patients should tell their healthcare professional about all prescription medicines, over-the-counter products, vitamins and herbal supplements they use.
Product Identification and Verification
The name Resiliva and the stated strengths are not enough to confirm a product’s identity, manufacturing origin or authorization status.
Before using any medicine, check the actual packaging and official documentation for:
The complete product name and active ingredient.
The stated strength and dosage form.
The manufacturer’s name and address.
Batch or lot number and expiry date.
Registration or authorization details applicable to the country.
The package insert and storage instructions.
If information is missing or inconsistent, consult a licensed pharmacist or the relevant national medicines regulatory authority. Do not assume that a product is genuine simply because it carries a familiar brand name or printed identification code.
Explore Resiliva and Resmetirom Information
This website can organize educational material into dedicated sections:
About Resiliva: Product identity, active ingredient and strength information.
Uses and Treatment: The defined role of resmetirom in MASH with liver fibrosis.
How Resmetirom Works: Its mechanism of action and metabolic effects.
Dosage and Administration: Reference-product dosing principles and important administration considerations.
Clinical Information: Clinical evidence, endpoints and limitations.
Safety Information: Warnings, monitoring and drug interactions.
Side Effects: Reported adverse reactions and symptoms requiring attention.
Product Verification: Packaging checks and responsible medicine sourcing.
Frequently Asked Questions: Answers to common questions about resmetirom and MASH.
Medical Disclaimer
This website is intended for general educational purposes only. Its content is not a substitute for professional medical advice, diagnosis, treatment or official prescribing information.
Resmetirom is a prescription medicine. Whether it is appropriate for an individual depends on the diagnosis, fibrosis stage, other health conditions, concurrent medicines and applicable local authorization.
Information about REZDIFFRA must not be treated as proof that Resiliva has the same formulation, manufacturer, approval or prescribing instructions. Always consult a qualified healthcare professional and verify the specific product through reliable official sources before use.
References
U.S. Food and Drug Administration. Current REZDIFFRA prescribing information.
U.S. Food and Drug Administration. REZDIFFRA approval and regulatory information.
European Medicines Agency. REZDIFFRA European public assessment and product information.
Madrigal Pharmaceuticals. Official resmetirom and REZDIFFRA information.
These sources support information about resmetirom and the reference product. Resiliva-specific product claims require supporting documentation applicable to Resiliva.
Latest News
FAQs
Resmetirom belongs to the class of selective thyroid hormone receptor beta, or THR-β, agonists. It is designed to act primarily on thyroid hormone receptor beta pathways in the liver.
Resiliva is identified on this website as a product containing resmetirom. Its specific prescription status and regulatory authorization should be verified according to the applicable country and product documentation.
THR-β stands for thyroid hormone receptor beta, a receptor involved in regulating important metabolic processes, particularly in the liver. Resmetirom activates this receptor to influence hepatic lipid metabolism.
Yes. The current U.S. indication for the reference product specifies that resmetirom is used together with diet and exercise for eligible adults with noncirrhotic NASH and moderate to advanced liver fibrosis.
No. The approved treatment population is specific and depends on factors such as the type of liver disease, presence of fibrosis and whether cirrhosis is present. A healthcare professional should determine whether treatment is appropriate.
MASH is the newer term for metabolic dysfunction-associated steatohepatitis, while NASH stands for nonalcoholic steatohepatitis. The terminology has evolved as understanding and classification of fatty-liver disease have changed.
The current U.S. reference-product regimen is once daily. Patients should follow the timing and administration instructions provided by their healthcare professional and the applicable product information.
The current U.S. prescribing information for the reference product states that the tablets should be swallowed whole and should not be split, crushed or chewed.
Fibrosis describes the amount of scar tissue in the liver. The current U.S. indication specifically concerns adults with noncirrhotic NASH and moderate to advanced fibrosis consistent with F2–F3 disease.
The website identifies Resiliva as containing resmetirom, but product-specific manufacturer and regulatory details have not been established here. Verification helps distinguish the specific product from the established reference product, Rezdiffra.